{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:05:11Z","timestamp":1784099111616,"version":"3.55.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Clear cell renal cell carcinoma (ccRCC) is a kidney cancer in which immune activity is closely intertwined with von Hippel-Lindau (VHL) loss, hypoxia-inducible factor (HIF) signaling, angiogenesis, hypoxia, and metabolic adaptation. Although immune checkpoint inhibitor (ICI)-based regimens have changed the treatment landscape of advanced ccRCC, only a subset of patients achieve durable benefit. Commonly used biomarkers, such as programmed death-ligand 1 (PD-L1) expression, tumor mutation burden (TMB), and broad inflammatory gene signatures, have not been sufficient to explain this variation or to guide routine treatment selection. One reason is that immune infiltration in ccRCC is not synonymous with effective antitumor immunity. A tumor rich in CD8+ T cells may still be resistant if these cells are exhausted, metabolically restricted, spatially separated from tumor nests, or surrounded by suppressive myeloid, stromal, and vascular programs. Therefore, the key issue is not simply whether a tumor is immunologically \u201chot\u201d or \u201ccold,\u201d but which part of the antitumor response has failed. In this Mini Review, we discuss ccRCC immunotherapy response from an immune-ecological perspective. We focus on several treatment-relevant immune states, including T-cell-inflamed but dysfunctional tumors, myeloid-dominant suppressive tumors, angiogenesis- and hypoxia-skewed tumors, and immune-excluded tumors. We also consider how bulk transcriptomics, single-cell and spatial profiling, T-cell receptor sequencing, proteomics, metabolomics, and longitudinal liquid biopsy may help define these ecotypes and capture treatment-induced remodeling. This perspective may support more refined patient stratification and more mechanism-matched immunotherapy strategies in ccRCC.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1893607","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:10:15Z","timestamp":1784095815000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping therapy-responsive immune ecotypes in clear cell renal cell carcinoma through integrative omics"],"prefix":"10.3389","volume":"17","author":[{"given":"Zheng","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, Suzhou Ninth People's Hospital","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"He","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, The Second Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Suzhou Ninth People's Hospital","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanle","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Suzhou Ninth People's Hospital","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2011.06.001","article-title":"Targeting the HIF2-VEGF axis in renal cell carcinoma","volume":"26","author":"Choueiri","year":"2020","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-019-0211-5","article-title":"The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications","volume":"16","author":"Linehan","year":"2019","journal-title":"Nat Rev Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02563-2","article-title":"Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients","volume":"69","author":"Qi","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2016.103","article-title":"Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma","volume":"13","author":"Carlo","year":"2016","journal-title":"Nat Rev Urol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2021.12.004","article-title":"Discovering dominant tumor immune archetypes in a pan-cancer census","volume":"185","author":"Combes","year":"2022","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ccell.2021.03.007","article-title":"Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy","volume":"39","author":"Krishna","year":"2021","journal-title":"Cancer Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13059-016-1092-z","article-title":"Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures","volume":"17","author":"Senbabaoglu","year":"2016","journal-title":"Genome Biol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1038\/s41598-021-83767-z","article-title":"Immune classification of clear cell renal cell carcinoma","volume":"11","author":"Su","year":"2021","journal-title":"Sci Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.cell.2017.04.016","article-title":"An immune atlas of clear cell renal cell carcinoma","volume":"169","author":"Chevrier","year":"2017","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1836-5","article-title":"An intra-tumoral niche maintains and differentiates stem-like CD8 T cells","volume":"576","author":"Jansen","year":"2019","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ccell.2021.10.001","article-title":"Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma","volume":"39","author":"Au","year":"2021","journal-title":"Cancer Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression \u2014 implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1016\/j.cell.2021.04.038","article-title":"Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages","volume":"184","author":"Obradovic","year":"2021","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-19-0499","article-title":"Tumor microenvironment dynamics in clear-cell renal cell carcinoma","volume":"9","author":"Vuong","year":"2019","journal-title":"Cancer Discov"},{"key":"B19","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00128-0","article-title":"Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial","volume":"23","author":"Vano","year":"2022","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.03.002","article-title":"Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes","volume":"42","author":"Saliby","year":"2024","journal-title":"Cancer Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2025.05.009","article-title":"Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma","volume":"39","author":"Bi","year":"2021","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2103240118","article-title":"Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ccell.2021.02.013","article-title":"Progressive immune dysfunction with advancing disease stage in renal cell carcinoma","volume":"39","author":"Braun","year":"2021","journal-title":"Cancer Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","article-title":"Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer","volume":"55","author":"Meylan","year":"2022","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","year":"2013","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-1128","article-title":"Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting","volume":"21","author":"Beuselinck","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adv5457","article-title":"Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and BAP1 loss","volume":"12","author":"Camp","year":"2026","journal-title":"Sci Adv"},{"key":"B32","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1158\/1538-7445.am2019-2458","article-title":"Integrated proteogenomic characterization of clear cell renal cell carcinoma","volume":"179","author":"Clark","year":"2019","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2026.05.007","article-title":"Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma","author":"Vuong","year":"2026","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2313906","article-title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0802","article-title":"LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1\/PD-L1 therapy","volume":"19","author":"Motzer","year":"2023","journal-title":"Future Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0283","article-title":"LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma","volume":"19","author":"Choueiri","year":"2023","journal-title":"Future Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00097-9","article-title":"Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1893607\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:10:16Z","timestamp":1784095816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1893607\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2026.1893607"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1893607","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1893607"}}